GPCR – structure therapeutics inc. - american depositary shares (US:NASDAQ)
Stock Stats
News
Structure Therapeutics (GPCR) valuation check after Phase 1 obesity candidate ACCG-2671 enters first-in-human trial [Yahoo! Finance]
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity [Yahoo! Finance]
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Structure Therapeutics (NASDAQ:GPCR) was upgraded by analysts at Wall St
Form 8-K Structure Therapeutics For: Dec 09
Form 424B5 Structure Therapeutics
Form 4 Structure Therapeutics For: Dec 08 Filed by: FMR LLC
Form 424B5 Structure Therapeutics
Form 8-K Structure Therapeutics For: Dec 08
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.